In the media
Science December 14, 2023
Breakthrough of the Year: How weight loss drugs offer benefits beyond the scale
Weight loss medications like Ozempic and Wegovy are examples of GLP-1 receptor agonist drugs. By mimicking a hormone produced in the body, this class of drugs has proven to be an effective way to treat diabetes and, more recently, obesity. This year, clinical trials revealed their beneficial effects on other chronic conditions that can be associated with obesity like heart failure and kidney disease. Despite their widespread and growing use, GLP-1 receptor agonist drugs were by no means an overnight success – decades of developments, unexpected discoveries, and some notable failures all paved the way to the 2023 Breakthrough of the Year.
Lilly November 8, 2023
After semaglutide, the second obesity drug, tirzepatide (Zepbound), has now been approved in the United States
Competition appears to be coming for the Danish pharmaceutical company Novo Nordisk in the market for medicines for chronic weight management. Semaglutide (marketed by the Danes under the names Wegovy and Ozempic) is no longer the only officially approved anti-obesity drug in the United States. The drug authority FDA has announced that it has now also approved Eli Lilly's dual GIP and GLP-1 agonist tirzepatide, sold under the name Zepbound, for chronic weight management.
Novo Nordisk August 8, 2023
Semaglutide 2.4 mg reduces risk of major cardiovascular disease by 20% in overweight or obese adults in SELECT trial
On August 8, 2023, Novo Nordisk announced the main results of the SELECT study of cardiovascular outcomes. The study compared a once-weekly injection of semaglutide 2.4 mg with placebo as an add-on to standard of care for the prevention of major cardiovascular disease over a period of up to five years.
Volkskrant 27 July 2023
From what age does our muscle mass decrease and what can we do about it?
With age, human muscle mass decreases. How bad is that, and can it be prevented?
NRC April 1, 2023
A serious medicine to lose some pounds
A new drug against serious obesity is so effective that there is a worldwide shortage of it. New, even better resources are on their way.
NRC 1 August 2022
Burn fat? Then training hard is not the solution
Losing weight through hard training is difficult, because it makes you hungry. New research shows that you digest more fat during light-intensity exercise, so go for a walk or jog.
Netherlands 1 April 2022
Obesity medicine reimbursed by health insurance from 1 April
From 1 April 2022, a small group of patients with serious obesity will be entitled to reimbursement from their Health insurance even if they only have a so-called “Basis verzekering”.
European Commission 21 January 2022
Wegovy™ approved for the treatment of obesity in EU
The European Commission has approved Wegovy™ (semaglutide) for chronic weight management in adults with obesity
FDA June 2021
FDA Approves New Drug Treatment
For the first time since 2014, the FDA approves
a new weight loss method.
NPO Radio 1
“the panacea that suppresses the appetite” “a game changer”
Broadcast NPO radio 1 of February 11, 2021.
HP/The Time
Lose weight through a shot
The time may soon be here: people with obesity can have a drug injected that leads to spectacular weight loss at high doses. But only lifestyle changes address the real causes.
Read more>
Daily Mail
How do I know the fat jab works?
Because I'm on it! As it's claimed a drug for diabetes can aid dramatic weight loss, bringing hope to millions, SARAH VINE reveals how it has changed her life
Read more>
Linda.nl
Danish company successfully markets weight-loss drug for obese patients
The Danish company Novo Nordisk markets slimming medicine. The medication ensures that a feeling of satiety occurs sooner, so that the person who has it injected eats less.
Read more>
Any questions? Contact us via Whatsapp
Send a message